Abstract
This report assesses the RNA interference market for drug R&D. RNA
interference (RNAi) has been hailed in the science media as the hottest
technical breakthrough in bioscience in the last ten years. A 2006 Nobel
Prize was awarded to the two scientists that discovered this important
biological effect.
RNAi allows scientists to disrupt or silence the expression of a gene being
studied. RNAi can also be used as a therapeutic agent. This field has quickly
emerged as a fast growing young market. The report provides the WW outlook
and market trends.
This must-have report discusses how an expanding number of companies have
created a vibrant commercial market that has segmented into different areas of
life science research and drug R&D. The market might be worth billions in a
few years.
This study reviews the market landscape and analyzes the players. The market
areas studied range from life science research products and services to
therapeutics or drug delivery tools for RNAi agents.
The report discusses RNAi topics including dsRNA, shRNA, siRNA, ddRNA, miRNA,
RNAi-as-drug, and targeted disease areas. This study analyzes RNAi deals
including M&As, alliances and examples of patent considerations. For example,
a number of big pharma companies are developing drugs with RNAi and have
either licensed or partnered with RNAi R&D companies. One big pharma acquired
a leading RNAi developer.
This report is designed for people that include marketers, business
development, top executives, investors, VCs, consultants, R&D managers,
entrepreneurs and etc. The report includes 39 detailed tables and figures
that provide key data about items such as strategic alliances, M&As, market
size, segments and so on.
Twenty company profiles provide the reader a snapshot of the companies' focus
or activities. This PDF formatted report is searchable by using key words.
Internet links help readers access companies' own web sites for further review.
| 
View Cart
